AI–Assisted News Report
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disorder marked by chronic synovial inflammation, leading to cartilage and bone degradation in diarthrodial joints. Affecting approximately 0.5–1% of the global population, RA arises from complex interactions among genetic, environmental, and immunological factors.
Dendritic cells (DCs), pivotal antigen-presenting cells in innate immunity, contribute to RA chronic inflammation by priming autoantigen-specific T cells and promoting autoantibody production against post-translationally modified proteins, such as citrullinated and carbamylated peptides. Recent evidence points to extracellular microvesicles (EMVs)—small, plasma membrane-derived particles—as potential mediators in RA pathogenesis due to their elevated presence in patients’ biological fluids and their capacity to transport bioactive molecules.
A new study by Buttari et al., published on March 5, 2025, in Frontiers in Immunology, investigates the role of EMVs from RA patients in modulating DC function. This research provides novel insights into how EMVs may perpetuate RA inflammatory microenvironment, offering potential implications for therapeutic strategies.
The aim of this study was to determine whether EMVs isolated from RA patients naive to biological disease-modifying anti-rheumatic drugs (DMARDs) can activate immature monocyte-derived DCs from healthy donors. The researchers hypothesized that EMVs, enriched with citrullinated and carbamylated proteins, induce phenotypic and functional maturation of DCs, thereby amplifying immune responses in RA. This builds on prior observations of increased EMV concentrations in RA plasma and their association with autoantigen presentation, as reported by the same group in earlier studies.
The study enrolled seven RA patients meeting the 2010 ACR criteria, all untreated with biological DMARDs, and seven age- and sex-matched healthy donors (HDs). Peripheral blood samples were processed to obtain platelet-poor plasma EMVs and tested for their capability to activate DCs from healthy donors.
Key Findings
NanoSight analysis showed significantly higher concentrations of EMVs in RA patients (6.18 × 10⁸ ± 2.52 × 10⁷ MVs/mL) compared to healthy donors (HDs) (3.96 × 10⁸ ± 1.51 × 10⁷ MVs/mL). Western blot analysis further confirmed increased levels of citrullinated and carbamylated proteins in EMVs derived from RA patients, supporting their involvement in autoantibody production.
Dendritic cells exposed to RA-derived EMVs showed a significant increase in mean fluorescence intensity for CD83 and CD86, compared to those treated with HD EMVs or left untreated, indicating phenotypic maturation. After 18 hours, the proportion of DCs positive for CD83, CD86, HLA-DR, and CD80 also significantly increased, resembling the effects seen with LPS stimulation.
At the molecular level, RA EMVs induced robust phosphorylation of p38, ERK, and NF-κB p65 in DCs, comparable to LPS-induced activation and significantly exceeding levels observed with HD EMVs or untreated controls. In mixed lymphocyte reaction assays, DCs stimulated with RA EMVs enhanced T-cell proliferation, reflecting increased allostimulatory capacity, and also elevated the production of IL-12p70, IL-1β, and IL-10 in DC supernatants.
Discussion and Implications
This study demonstrates that EMVs from RA patients act as potent activators of DCs, driving both phenotypic and functional maturation. The presence of post-translationally modified proteins on RA EMVs likely contributes to their immunostimulatory effects, potentially by presenting neoepitopes that trigger autoimmune responses. The activation of MAPK (p38, ERK) and NF-κB pathways aligns with known mechanisms of DC maturation and inflammation, reinforcing the hypothesis that EMVs amplify RA inflammatory milieu.
Figure 1. EMVs from patients with RA carry carbamylated and citrullinated proteins and trigger DC activation in vitro stimulating allogeneic T cell proliferation. Rheumatoid Arthritis (RA); Extracellular microvesicles (EMVs); carbamylated proteins (CarbP); citrullinated proteins (CP); Healthy donors (HDs); PBMCs (peripheral blood mononuclear cells); GM-CSF (Granulocyte-macrophage colony-stimulating factor); IL-4 (Interleukin 4); moDC (monocyte-derived dendritic cell); Cluster of differentiation 83 (CD83); Cluster of differentiation 86 (CD86); Human Leukocyte Antigen-DR isotype (HLA-DR); Cluster of differentiation 80 (CD80); phospho-p38 (P-p38); phospho-extracellular signal-regulated kinases (P-ERK); nuclear factor‐kappa B (NF‐kB); Interleukin-12p70 (IL-12p70); Interleukin-1b (IL-1b); Interleukin-10 (IL-10).
For the authors, these findings highlight EMVs as key players in RA pathogenesis, extending beyond passive carriers to active modulators of immune function. The elevated EMV levels in RA patients, coupled with their bioactivity, suggest a dose-dependent contribution to disease severity, consistent with prior correlations between EMV concentrations and RA activity. The dual cytokine response (pro-inflammatory IL-12p70 and IL-1β alongside regulatory IL-10) warrants further exploration to clarify its net impact on T-cell differentiation and inflammation.
Therapeutically, targeting EMV production, release, or DC interactions could offer novel strategies to mitigate RA progression. Inhibitors of EMV biogenesis or signaling pathway blockers (e.g., MAPK or NF-κB inhibitors) might reduce DC activation and downstream inflammation. Additionally, EMVs could serve as biomarkers for monitoring disease activity or therapeutic response, given their distinct molecular profile in RA.
A key limitation of this study is that the authors only examined the effects of EMVs in monocyte-derived DCs, while other DC subsets, such as myeloid and plasmacytoid DCs, play important roles in RA and may respond differently to RA EMVs. The small cohort size also restricts generalizability, necessitating larger-scale validation. Future research should identify specific EMV cargo molecules driving DC activation and explore subset-specific responses. Longitudinal studies correlating EMV profiles with clinical outcomes could further establish their biomarker potential.
Conclusion
Buttari et al.’s investigation provides compelling evidence that EMVs from RA patients enhance DC activation, offering a new perspective on their role in sustaining chronic inflammation. Published in Frontiers in Immunology, this work underscores the need for continued research into EMV-mediated mechanisms in RA, with the potential to provide innovative diagnostic and therapeutic approaches for this debilitating disease.
Source:
Extracellular microvesicles from patients with Rheumatoid arthritis promote dendritic cell activation in vitro. Brigitta Buttari1, Serena Recalchi2, Gloria Riitano2, Antonella Capozzi2, Federica Maria Ucci3, Valeria Manganelli2, Federica Fratini4, Elisabetta Profumo1, Tina Garofalo2, Cristiano Alessandri3, Roberta Misasi2, Fabrizio Conti3, Agostina Longo2, Maurizio Sorice2* Front Immunol. 2025 Mar 5;16. doi.org/10.3389/fimmu.2025.1532114
Author Affiliations (original article):
1Department of Cardiovascular and Endocrine-metabolic Diseases, and Aging, Istituto Superiore di Sanità, Rome, Italy, 2Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy, 3Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, “Sapienza” University of Rome, Rome, Italy, 4Proteomics Core Facility, Istituto Superiore di Sanità, Rome, Italy.
Professional AI assistance:
This news report is assisted and generated by an Artificial Intelligence (AI) using the professional services of Zlatin Balevsky (contact@balevsky.ai).
Related stories you may like:
Pregnancy and Rheumatoid Arthritis
Sympathetic Nervous System Dysfunction in Rheumatoid Arthritis: Brief Overview
Vasoactive Intestinal Peptide Inhibits Pathogenic Th17 Cells from Rheumatoid Arthritis Patients
Stress and Worrying Affect Short-Term Fluctuations in Rheumatoid Arthritis Symptoms